Summary
The Cigna Group (CI) reported total revenues of $63.7 billion for the third quarter of 2024, a significant increase of 30% year-over-year, driven by robust growth in its Evernorth Health Services segment. Shareholders' net income for the quarter was $739 million, or $2.63 per diluted share, a decrease of 48% compared to the prior year, primarily due to a substantial impairment loss on equity securities related to its investment in VillageMD. Despite the decline in net income, adjusted income from operations, a non-GAAP measure that excludes special items like investment losses, increased by 5% to $2.1 billion, signaling underlying operational strength. The company's medical customer base saw a slight decrease of 3%, primarily impacting the Individual and Family Plans within the U.S. Healthcare segment. However, Evernorth's Pharmacy Benefit Services and Specialty and Care Services segments demonstrated strong revenue growth, supported by increased prescription drug utilization and customer expansion. The company is also advancing its strategic divestiture of its Medicare Advantage business, expected to close in the first quarter of 2025.
Financial Highlights
48 data points| Revenue | $63.69B |
| Cost of Revenue | $47.56B |
| Gross Profit | $16.13B |
| SG&A Expenses | $3.59B |
| Operating Income | $2.58B |
| Interest Expense | $380.00M |
| Net Income | $739.00M |
| EPS (Basic) | $2.65 |
| EPS (Diluted) | $2.63 |
| Shares Outstanding (Diluted) | 281.40M |
Key Highlights
- 1Total revenues surged 30% year-over-year to $63.7 billion, largely driven by a 36% increase in Evernorth Health Services revenue.
- 2Shareholders' net income declined 48% to $739 million, significantly impacted by a $2.7 billion impairment loss on its VillageMD equity investment.
- 3Adjusted income from operations, excluding special items, grew 5% to $2.1 billion, indicating operational resilience.
- 4Pharmacy and other service costs increased 41% to $47.6 billion, mirroring the revenue growth driven by higher prescription drug utilization.
- 5The company has entered into an agreement to sell its Medicare Advantage and related businesses to Health Care Service Corporation (HCSC) for approximately $3.7 billion, with an expected closing in Q1 2025.
- 6Selling, general, and administrative expenses decreased by 5% for the quarter, attributed to the absence of litigation settlements seen in the prior year's quarter.
- 7The company repurchased approximately $5.0 billion of common stock during the first nine months of 2024, including $3.2 billion under Accelerated Share Repurchase agreements.